Drug Costs Archives - Page 12 of 35 - ��ýҕ�l Health News

KHN’s ‘What the Health?’: 100 Days of Health Policy

It’s 100 days into Joe Biden’s presidency and a surprisingly large number of health policies have been announced. But health is notably absent from the administration’s $1.8 trillion spending plan for American families, making it unclear how much more will get done this year. Meanwhile, the Centers for Disease Control and Prevention loosens its mask-wearing recommendations for those who have been vaccinated, but the new rules are confusing. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Julie Appleby, who reported the latest KHN-NPR “Bill of the Month” episode.

April 29, 2021

FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar

A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?

By Harris Meyer

April 15, 2021

Podcast

KHN’s ‘What the Health?’: Planning for Round Two

The ink is barely dry on the recent covid relief bill, but Democrats in Congress and President Joe Biden are wasting no time gearing up for their next big legislative package. Meanwhile, predictions of more states expanding Medicaid have proved premature. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Lauren Weber, who reported the latest KHN-NPR “Bill of the Month” episode.

April 1, 2021

How Much of Trump’s Health Agenda Has Biden Undone?

In his campaign, President Joe Biden promised to undo policies, particularly health policies, implemented by former President Donald Trump. Yet, despite immense executive power, reversing four years of action takes time and resources.

By Julie Rovner

March 25, 2021

Podcast

KHN’s ‘What the Health?’: Getting Down to Work at HHS

After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.

March 25, 2021

Democrats Eye Medicare Negotiations to Lower Drug Prices

Progressive and conservative Democratic lawmakers, as well as President Joe Biden, are in favor of authorizing federal officials to negotiate with drugmakers over what Medicare pays for at least some of the most expensive brand-name drugs and to base those prices on the drugs’ clinical benefits. Such a measure could put Republicans in the uncomfortable position of opposing an idea that most voters from both parties generally support.

By Emmarie Huetteman

March 23, 2021

As Drug Prices Keep Rising, State Lawmakers Propose Tough New Bills to Curb Them

The measures would impose taxes on increases in the price of drugs that don’t reflect improved clinical value and set the rates paid by state-run and commercial health plans to a benchmark based on prices in Canada.

By Harris Meyer

Feb. 12, 2021

States Move Ahead With Canada Drug Importation While Awaiting Signal From Biden

As president, Donald Trump encouraged states to bring in drugs from Canada, where prices are cheaper. It’s not clear if the new administration will follow suit.

By Phil Galewitz

Jan. 29, 2021

COVID-19

Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers

With U.S. cases skyrocketing, demand for Gilead’s dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.

By Sarah Jane Tribble

Jan. 27, 2021

Biden Promise Tracker

Health Issues Carried Weight on the Campaign Trail. What Could Biden Do in His First 100 Days?

KHN has teamed up with PolitiFact to track what becomes of President Joe Biden’s 2020 campaign promises over the next four years. As he moves into the West Wing, what are his chances of making progress on health care?

By Victoria Knight

Jan. 22, 2021

Even With Senate Control, Democrats Will Need Buy-In From GOP on Key Health Priorities

With a majority too small to eliminate the filibuster, Democrats will not have enough votes in the Senate to pass many of their plans without Republicans and will also have only a razor-thin majority in the House. This combination could doom many Democratic health care proposals, like offering Americans a government-sponsored public insurance option, and complicate efforts to pass further pandemic relief.

By Emmarie Huetteman

Jan. 11, 2021

Biden’s First Order of Business May Be to Undo Trump’s Policies, but It Won’t Be Easy

President Donald Trump made substantial changes to the nation’s health care system using executive branch authority. But reversing policies that Democrats oppose would take time and personnel resources, competing with other priorities of the new administration.

By Julie Rovner

Jan. 8, 2021

Many Health Plans Now Must Cover Full Cost of Expensive HIV Prevention Drugs

Most private insurance will be required to cover drugs, like Truvada, that offer protection against HIV infection, without making plan members share the cost.

By Michelle Andrews

Jan. 5, 2021

Seniors Face Crushing Drug Costs as Congress Stalls on Capping Medicare Out-Of-Pockets

While many private insurers cap what members pay in health costs, Medicare does not. Democrats and Republicans in Congress have proposed annual limits ranging from $2,000 to $3,100. But there’s disagreement about how to pay for that cost cap.

By Harris Meyer

Jan. 4, 2021

Podcast

KHN’s ‘What the Health?’: 2020 in Review — It Wasn’t All COVID

The coronavirus pandemic colored just about everything in 2020. But there was other health policy news that you either never heard or might have forgotten about: the Affordable Care Act going before the Supreme Court with its survival on the line; ditto for Medicaid work requirements. And a surprise ending to the “surprise bill” saga. Joanne Kenen of Politico, Anna Edney of Bloomberg News and Sarah Karlin-Smith of Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.

Dec. 23, 2020

Surprise Federal Drug Rule Directs Insurers to Reveal What They Pay for Prescription Drugs

A provision the Trump administration tucked into its final rule on health plan price transparency requires telling consumers what they will pay out-of-pocket for drugs and showing them what the plan paid.

By Harris Meyer

Nov. 19, 2020

A $200 Debit Card Won’t Do Much for Seniors’ Drug Costs

President Donald Trump wants to send seniors $200 apiece. Beyond the legal and logistical problems, health care experts point out it does little to help someone with even typical prescription costs.

By Harris Meyer

Oct. 30, 2020

Florida Fails to Attract Bidders for Canada Drug Importation Program

No private firms bid on the $30 million contract to set up and operate the state’s plan to bring in cheaper drugs. The setback is likely to delay by at least several months Florida’s effort to become the first state to import drugs under new federal regulations.

By Phil Galewitz

Oct. 26, 2020

KHN & PolitiFact HealthCheck

Progressive Group Highlights Trump, Tillis Weakness on Insulin Price Tags

The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.

By Aneri Pattani

Oct. 20, 2020

Not Pandemic-Proof: Insulin Copay Caps Fall Short, Fueling Underground Exchanges

Although sharing prescription medicines is illegal, many people with diabetes are turning to underground donation networks when they cannot afford their insulin. Caps on insulin copays enacted in Colorado and 11 other states were designed to help. But the gaps between insulin costs and many patients’ financial realities are only widening amid the economic crisis of the COVID pandemic.

By Markian Hawryluk

Oct. 5, 2020

��ýҕ�l

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics

Drug Costs